Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riastap and FIBTEM for Postpartum Hemorrhage
NCT02528708Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in postpartum hemorrhage (PPH) comparing Fibrinogen concentrate with Placebo (2 arms). Primary endpoint: Maximum Clot Firmness at 24 hours. Planned start Jan 2021; status: withdrawn.
02
Drugs
Fibrinogen human
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT02528708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528708.